Opioid Use Disorder: Medical Treatment Options

被引:0
|
作者
Coffa, Diana [1 ]
Snyder, Hannah [1 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA
关键词
EXTENDED-RELEASE NALTREXONE; PRIMARY-CARE; ASSISTED TREATMENT; CHRONIC PAIN; BUPRENORPHINE; METHADONE; NALOXONE; DEPENDENCE; OUTCOMES; MULTICENTER;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, patients are more likely to enter full recovery. Methadone and buprenorphine are opioid agonists that reduce mortality, opioid use, and HIV and hepatitis C virus transmission while increasing treatment retention. Intramuscular naltrexone is not as well studied and is harder to initiate than opioid agonists because of the need to abstain for approximately one week before the first dose. However, among those who start naltrexone, it can reduce opioid use and craving. Choosing the correct medication for a given patient depends on patient preference, local availability of opioid treatment programs, anticipated effectiveness, and adverse effects. Discontinuation of pharmacotherapy increases the risk of relapse; therefore, patients should be encouraged to continue treatment indefinitely. Many patients with opioid use disorder are treated in primary care, where effective addiction treatment can be provided. Family physicians are ideally positioned to diagnose opioid use disorder, provide evidence-based treatment with buprenorphine or naltrexone, refer patients for methadone as appropriate, and lead the response to the current opioid crisis. Copyright (C) 2019 American Academy of Family Physicians.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 50 条
  • [1] Opioid Use Disorder: Diagnosis and Updated Treatment Options
    Li, Benjamin T.
    Riordan, Nina
    Banu, Sophia
    Murtaza, Syed
    Shah, Asim A.
    [J]. PSYCHIATRIC ANNALS, 2018, 48 (08) : 366 - 371
  • [2] Misrepresentation of Options for Treatment of Opioid Use Disorder in the General Hospital
    Grekin, Paul
    Saxon, Andrew
    Iles-Shih, Matt
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2024, 181 (02): : 169 - 170
  • [3] Opioid Use Disorder and Older Adults: Navigating Treatment Options
    Brandt, Nicole J.
    [J]. JOURNAL OF GERONTOLOGICAL NURSING, 2022, 48 (07): : 4 - 9
  • [4] Treatment of Opioid Use Disorder in Pediatric Medical Settings
    Sharon Levy
    Deepa Camenga
    [J]. Current Addiction Reports, 2019, 6 : 374 - 382
  • [5] Treatment of Opioid Use Disorder in Pediatric Medical Settings
    Levy, Sharon
    Camenga, Deepa
    [J]. CURRENT ADDICTION REPORTS, 2019, 6 (04) : 374 - 382
  • [6] Treatment of Refractory Opioid Use Disorder Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: A Narrative Review
    Kimmel, Simeon
    Bach, Paxton
    Walley, Alexander Y.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (06) : 1793 - 1793
  • [7] A Call for Medical Schools to Teach Opioid Use Disorder Treatment
    Shapiro, Aaron M.
    [J]. ACADEMIC MEDICINE, 2019, 94 (12) : 1843 - 1843
  • [8] Treatment of Refractory Opioid Use DisorderComparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: A Narrative Review
    Simeon Kimmel
    Paxton Bach
    Alexander Y. Walley
    [J]. Journal of General Internal Medicine, 2021, 36 : 1793 - 1793
  • [9] Understanding and co-managing medication treatment options for opioid use disorder
    Abigail Kay
    Rachel Shmuts
    Melanie Beck
    [J]. Internal and Emergency Medicine, 2022, 17 : 2159 - 2165
  • [10] Understanding and co-managing medication treatment options for opioid use disorder
    Kay, Abigail
    Shmuts, Rachel
    Beck, Melanie
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (07) : 2159 - 2165